MS behandling og oppfølging under COVID-19 pandemien
Publisert:
- Zhovtis Ryerson L, Frohman TC, Foley J, et al. . Extended interval dosing of natalizumab in multiple sclerosis. . J Neurol Neurosurg Psychiatry 2016. pmid: 26917698 PubMed
- Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. . Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019. pmid:30956686 PubMed
- Yamout BI, Sahraian MA, Ayoubi NE, Tamim H, Nicolas J, Khoury SJ, et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord 2018 Aug;24:113-6. PubMed
- Kaufman M, Cree BA, de SJ, Fox RJ, Gold R, Hartung HP, et al. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol 2015 Feb;262(2):326-36. PubMed
- Fox RJ, Cree BA, de SJ, Gold R, Hartung HP, Jeffery D, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014 Apr 29;82(17):1491-8. PubMed
- Zhovtis RL, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm 2020 Mar;7(2).
- Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 2019 Jun;31:65-71. PubMed
- Juto A, Fink K, Al NF, Piehl F. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord 2020 Jan;37:101468. PubMed